In addition to utilizing an immunohistochemical method to verify that IL6, a potential regulatory biomarker, in BOTs does have a significantly higher performance than controls, IL6 has certain accessorial functions associated with nearby immune-related cells in the microenvironment for the enhancement of benign or malignant ovarian tumors [53,54,55,56,64,65]. The gene discussed is IL6; the disease is ovarian cancer.